Stroke is a major public health challenge in China, with high incidence rate, high disability rate, high recurrence rate and other characteristics. According to data, there will be approximately 4.23 million new cases of stroke and 26.68 million current cases in China in 2023, indicating an urgent need for medication. It is reported that recently, the pharmaceutical industry has received heavy news, with the National Medical Products Administration (NMPA) approving a Class 1 innovative drug for market launch.
According to the National Medical Products Administration (NMPA) on October 26th, the NMPA has approved Bayer AG's application for Class 1 innovative drug, Asuksen tablets (trade name: Shuhuabo), through a priority review and approval process. It is used to reduce the risk of stroke in adult patients with ischemic stroke or high-risk transient ischemic attack (TIA), excluding patients with cardioembolic stroke, providing a new treatment option for patients.
The approval of this drug is based on positive data from the globally critical Phase III OCEANIC-STROKE study. This study is the first successful FXIa inhibitor phase III stroke study to achieve positive results. FXIa is located in a critical link of the endogenous coagulation pathway, mainly involved in the formation and amplification of pathological thrombi, with relatively limited impact on normal physiological hemostasis. Ashuksen aims to break through the clinical dilemma of "increased efficacy often accompanied by increased bleeding" in traditional intensified antithrombotic therapy by selectively inhibiting FXIa, and provide additional protection on the basis of existing antiplatelet therapy.
Someone pointed out that the results of the OCEANIC-STROKE study showed that in non cardioembolic ischemic stroke or high-risk TIA patients receiving monotherapy (SAPT) or dual antiplatelet therapy (DAPT), compared with placebo, the combination of FXIa inhibitor Asuksen treatment can significantly reduce the risk of ischemic stroke by 26%, and does not increase the risk of major bleeding defined by the International Society of Thrombosis and Hemostasis (ISTH). In key subgroups such as age, gender, type of first event, subtype of non cardiogenic stroke, stroke severity, and planned antiplatelet therapy, the treatment efficacy was consistent, supporting its potential application in a wide patient population.
With the aging population, accelerated urbanization, and the prevalence of unhealthy lifestyles among residents, the disease burden is growing explosively, and the market prospects for stroke related therapeutic drugs are promising. It is reported that not only overseas innovation achievements have been achieved, but also domestic pharmaceutical enterprises have continued to promote the stroke track, and a number of new drugs have steadily promoted clinical and application, demonstrating local innovation strength.
As stated by Qianhong Pharmaceutical at the performance briefing, the company's QHRD106 injection (acute ischemic stroke) project is currently in the phase IIb clinical closure stage. After completing communication and exchange with the national CDE, the related work of phase III clinical and market application will be promptly promoted.
The independently developed stroke thrombolysis candidate drug SIM0811 by Xiansheng Pharmaceutical has initiated phase I clinical trials and completed the first subject enrollment. As a newly developed stroke candidate drug independently developed by the company, the smooth progress of its clinical research is expected to form a synergy with the already marketed multi-target brain cell protectant Xianbixin, providing a more comprehensive treatment for ischemic stroke patients.
The new drug marketing authorization application (NDA) for Class 1 injection Y-3 (Lobemil for Injection) proposed by Kangzhe Pharmaceutical for the treatment of acute ischemic stroke has been accepted by the National Medical Products Administration. This product is the first multi-target brain cell protector targeting PSD95 nNOS and MPO, and has excellent therapeutic effects on ischemic stroke and potential preventive effects on post-stroke depression and anxiety symptoms.
The heavy disease burden of stroke calls for more safe and effective treatment drugs. The approval of Bayer Ashuksen tablets provides patients with a new solution and brings them new hope. But stroke prevention and treatment is a systematic project, and we look forward to accelerating the transformation and implementation of innovative achievements at home and abroad, continuously enriching the domestic stroke drug matrix, improving the full chain treatment options from acute phase treatment to recurrence prevention, helping to reduce the risk of disease disability and recurrence, and safeguarding national health.